Author

Roberto Ria

Universit

Biography

Dr. Roberto Ria is a researcher and a scientist at  Department of Internal Medicine and clinical oncology and has specializtion in cancer, lymphoma, myeloma, orthosarcoma, chondrosarcoma, Bone cancer, Fibroblast, angiogenesis, Multiple myeloma, Osteosarcoma
Title
Cited by
Year
Halting the vicious cycle within the multiple myeloma ecosystem: Blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression
AG Solimando, MC Da Vià, P Leone, P Borrelli, GA Croci, P Tabares, ...haematologica 106 (7), 1943, 2021202
46
2021
Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus
S Jolles, M Michallet, C Agostini, MH Albert, D Edgar, R Ria, L Trentin, ...European Journal of Haematology 106 (4), 439-449, 2021202
26
2021
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department
AG Solimando, N Susca, P Borrelli, M Prete, G Lauletta, F Pappagallo, ...Frontiers in Medicine 7, 625176, 2021202
22
2021
Anti-VEGF drugs in the treatment of multiple myeloma patients
R Ria, A Melaccio, V Racanelli, A VaccaJournal of Clinical Medicine 9 (6), 1765, 2020202
21
2020
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases …
M Gentile, G Specchia, D Derudas, M Galli, C Botta, S Rocco, ...haematologica 106 (1), 291, 2021202
16
2021
Telemedicine DSS-AI multi level platform for monoclonal gammopathy assistance
A Massaro, A Galiano, D Scarafile, A Vacca, A Frassanito, A Melaccio, ...2020 IEEE International Symposium on Medical Measurements and Applications …, 2020202
14
2020
Right heart changes impact on clinical phenotype of amyloid cardiac involvement: a single centre study
S Cicco, AG Solimando, R Buono, N Susca, G Inglese, A Melaccio, ...Life (), 247, 2020202
10
2020
Myeloma cells regulate miRNA transfer from fibroblast‐derived exosomes by expression of lncRNAs
I Saltarella, A Lamanuzzi, V Desantis, L Di Marzo, A Melaccio, P Curci, ...The Journal of Pathology 256 (4), 402-413, 2022202
10
2022
Thrombopoietin promotes angiogenesis and disease progression in patients with multiple myeloma
A Lamanuzzi, I Saltarella, MA Frassanito, D Ribatti, A Melaccio, ...The American Journal of Pathology 11 (4), 748-758, 2021202
9
2021
Prognostic and therapeutic role of angiogenic microenvironment in thyroid cancer
A Melaccio, LI Sgaramella, A Pasculli, G Di Meo, A Gurrado, FP Prete, ...Cancers 13 (11), 2775, 2021202
9
2021
Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells
MT Palano, D Giannandrea, N Platonova, G Gaudenzi, M Falleni, D Tosi, ...Cancers 12 (9), 2600, 2020202
8
2020
Effect of thyroidectomy on circulating angiogenic cytokines in papillary thyroid carcinoma and benign goiter: Potential for new biomarkers?
R Ria, F Prete, A Melaccio, G Di Meo, I Saltarella, AG Solimando, ...Surgery 169 (1), 2-33, 2021202
7
2021
The bone marrow niche landscape: A journey through aging, extrinsic and intrinsic stressors in the haemopoietic milieu
AG Solimando, A Melaccio, A Vacca, R RiaJ. Cancer Metastasis Treat 8 (9), 2022202
7
2022
Imaging Evaluation of Pulmonary and Non-Ischaemic Cardiovascular Manifestations of COVID-19
S Cicco, A Vacca, C Cariddi, R Carella, G Altamura, AG Solimando, ...Diagnostics 11 (7), 1271, 2021202
6
2021
TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing
A Reale, T Khong, S Mithraprabhu, I Savvidou, J Hocking, K Bergin, ...Leukemia & Lymphoma 62 (2), 337-37, 2021202
4
2021
Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
A Melaccio, A Reale, I Saltarella, V Desantis, A Lamanuzzi, S Cicco, ...Journal of Clinical Medicine 11 (21), 691, 2022202
4
2022
The spectrum of ocular manifestations in patients with Waldenström’s macroglobulinemia
R Dammacco, W Lisch, TT Kivelä, E Terpos, E Kastritis, D Sisto, A Mavilio, ...Ocular Immunology and Inflammation 30 (7-8), 1659-1668, 2022202
4
2022
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
F Morabito, E Zamagni, C Conticello, V Pavone, S Palmieri, S Bringhen, ...European Journal of Haematology 108 (), 178-189, 2022202
3
2022
A challenging case of visceral leishmaniasis
AG Solimando, G Coniglio, V Desantis, G Lauletta, DF Bavaro, L Diella, ...Reports 5 (2), 2, 2022202
3
2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 …
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended ‐year follow‐up of a multicenter, retrospective clinical experience with 19 …A Bruzzese, D Derudas, M Galli, EA Martino, S Rocco, C Conticello, ...Hematological Oncology 40 (4), 704-715, 2022202
3
2022

Referred From: https://scholar.google.com/citations?user=Zde9w2wAAAAJ&hl=en&oi=ao

Cited by
Citations 12829
h-index 59
i10-index 136
Recommended Journals
Open Access Journals